RVMD · Revolution Medicines, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $343.97M | - | $262.51M | $224.13M | $205.75M | - | $151.75M | $134.93M | $118.02M | - |
| SG&A | $101.25M | - | $52.76M | $40.58M | $35.01M | - | $23.96M | $21.71M | $22.84M | - |
| Total Operating Expenses | $445.22M | - | $315.27M | $264.71M | $240.76M | - | $175.71M | $156.64M | $140.86M | - |
| D&A | $2.20M | - | $2.00M | $1.70M | $1.60M | - | $1.60M | $1.60M | $1.54M | - |
| Operating Income | ($445.22M) | - | ($315.27M) | ($264.71M) | ($240.76M) | - | ($175.71M) | ($156.64M) | ($140.86M) | - |
| Interest Expense | $12.20M | - | $11.43M | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Net Income | ($453.82M) | - | ($305.21M) | ($247.79M) | ($213.42M) | - | ($156.29M) | ($133.23M) | ($116.00M) | - |
| EPS - Basic | ($2.29) | - | ($1.61) | ($1.31) | ($1.13) | - | ($0.94) | ($0.81) | ($0.70) | - |
| EPS - Diluted | ($2.29) | - | ($1.61) | ($1.31) | ($1.13) | - | ($0.94) | ($0.81) | ($0.70) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $440.94M | $383.75M | $217.44M | $402.44M | $333.55M | $543.06M | $201.26M | $275.71M | $288.43M | $696.15M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $80.54M | $64.62M | $74.85M | $56.76M | $47.51M | $54.43M | $24.46M | $29.32M | $32.38M | $61.79M |
| Current Assets | $1.97B | $2.08B | $1.98B | $2.18B | $2.13B | $2.33B | $1.58B | $1.62B | $1.73B | $1.88B |
| Total Assets | $2.25B | $2.35B | $2.25B | $2.43B | $2.37B | $2.56B | $1.76B | $1.81B | $1.91B | $2.06B |
| Current Liabilities | $289.60M | $290.42M | $245.62M | $184.53M | $158.60M | $163.91M | $110.86M | $105.33M | $93.72M | $143.85M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $753.82M | $723.21M | $655.02M | $564.20M | $287.20M | $293.10M | $196.69M | $189.59M | $182.90M | $235.51M |
| Stockholders' Equity | $1.50B | $1.63B | $1.60B | $1.87B | $2.08B | $2.27B | $1.57B | $1.62B | $1.73B | $1.83B |
| Retained Earnings | ($3.32B) | ($2.87B) | ($2.50B) | ($2.20B) | ($1.95B) | ($1.74B) | ($1.54B) | ($1.39B) | ($1.25B) | ($1.14B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($354.17M) | - | - | - | ($194.44M) | - | - | - | ($160.56M) | - |
| Investing Cash Flow | $172.62M | - | - | - | ($15.95M) | - | - | - | ($247.97M) | - |
| Financing Cash Flow | $238.74M | - | - | - | $874.0K | - | - | - | $810.0K | - |
| CapEx | $1.54M | - | - | - | $3.27M | - | - | - | $3.17M | - |
| Free Cash Flow | ($355.70M) | - | - | - | ($197.70M) | - | - | - | ($163.73M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.78 | - | - | - | 0.93 | - | - | - | 1.41 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -20.1% | - | -13.6% | -10.2% | -9.0% | - | -8.9% | -7.4% | -6.1% | - |
| Return on equity | -30.3% | - | -19.1% | -13.3% | -10.3% | - | -10.0% | -8.2% | -6.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.80 | 7.14 | 8.05 | 11.79 | 13.46 | 14.20 | 14.24 | 15.42 | 18.45 | 13.06 |
| Quick ratio | 6.80 | 7.14 | 8.05 | 11.79 | 13.46 | 14.20 | 14.24 | 15.42 | 18.45 | 13.06 |
| Cash ratio | 1.52 | 1.32 | 0.89 | 2.18 | 2.10 | 3.31 | 1.82 | 2.62 | 3.08 | 4.84 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -36.5x | - | -27.6x | - | - | - | - | - | - | - |
| Equity multiplier | 1.50 | 1.44 | 1.41 | 1.30 | 1.14 | 1.13 | 1.13 | 1.12 | 1.11 | 1.13 |
| Liabilities / Assets | 0.33 | 0.31 | 0.29 | 0.23 | 0.12 | 0.11 | 0.11 | 0.10 | 0.10 | 0.11 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 12.8x | - | 5.5x | 3.7x | 3.2x | - | 4.8x | 4.0x | 3.1x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | -100.0% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -84.9% | - | -79.4% | -69.0% | -70.9% | - | -42.6% | - | -29.5% | - |
| Net income growth (YoY) | -112.6% | - | -95.3% | -86.0% | -84.0% | - | -44.1% | - | -18.0% | - |
| EPS growth (YoY) | -102.7% | - | -71.3% | -61.7% | -61.4% | - | 5.1% | - | 23.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -79.9% | - | - | - | -20.8% | - | - | - | -155.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -27.8% | -28.0% | 2.0% | 15.2% | 20.4% | 24.0% | 87.0% | - | 85.4% | 166.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$29.39M totalCollaboration Revenue$29.39M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Revolution Medicines against the 5 most active filers in the same SIC group.